Manufacturing agility could prove decisive if early studies show promising immune responses.
In the shadow of a spreading Bundibugyo Ebola outbreak across the Democratic Republic of the Congo and Uganda — 575 suspected cases, 148 suspected deaths, and no approved vaccine — humanity once again finds itself racing against a virus it was not fully prepared to meet. India's Serum Institute, alongside Oxford and CEPI, is staking its bet on the ChAdOx platform, the same architecture that helped the world through COVID-19, hoping that speed of manufacture can substitute, at least temporarily, for the depth of clinical evidence. It is a wager born not of recklessness but of necessity — the kind of moral arithmetic that emerges when the alternative is waiting while people die.
- A Bundibugyo Ebola outbreak has killed at least 148 people across DRC and Uganda, and for the first time in such a crisis, the world has no licensed vaccine to deploy against this specific strain.
- The WHO has declared a Public Health Emergency of International Concern, while the Africa CDC has elevated it to a Continental Security emergency, signaling that containment is already under severe pressure.
- The only available stockpile — 500,000 doses of Ervebo — was designed for the Zaire strain and may offer little or no protection against Bundibugyo, leaving frontline responders effectively unarmed.
- Serum Institute's ChAdOx candidate could produce doses in 20 to 30 days using existing infrastructure, but it has never been tested in animals or humans for this virus, forcing regulators into an agonizing safety-versus-urgency calculation.
- A global coalition including Gavi, CEPI, WHO, UNICEF, and the World Bank is coordinating emergency evaluation, but experts warn that even under the best conditions, a deployable vaccine may still be nine months away.
A Bundibugyo Ebola outbreak is tearing through the Democratic Republic of the Congo and Uganda with alarming speed. With 575 suspected cases, 51 confirmed infections, and 148 suspected deaths, the WHO has declared a Public Health Emergency of International Concern. The Africa CDC has gone further, calling it a Continental Security emergency. What makes this outbreak uniquely dangerous is not only its geography — conflict-affected, hard-to-reach regions with fragile health systems — but the absence of any approved vaccine designed to stop it.
Into that void steps an unlikely coalition: India's Serum Institute, the University of Oxford, and the Coalition for Epidemic Preparedness Innovations. Their shared instrument is the ChAdOx platform, the same viral vector technology behind the Oxford-AstraZeneca COVID-19 vaccine, which SII manufactured at massive scale as Covishield. The company believes it can produce doses within twenty to thirty days by leveraging infrastructure already optimized for this platform — a speed advantage that no other candidate can match.
The competing option, an rVSV-based candidate built on the same model as Ervebo — the licensed Zaire Ebola vaccine — faces a six-to-nine-month manufacturing delay just to produce trial-ready supplies. Gavi holds roughly 500,000 doses of Ervebo and has deployed it effectively in past DRC outbreaks, but experts caution it may offer little protection against the Bundibugyo strain.
The ChAdOx candidate's decisive weakness is its untested status: no animal studies, no human trials for Bundibugyo virus disease. A WHO adviser has warned that even an accelerated timeline could stretch nine months before any vaccine is ready for deployment. Regulators coordinating across Gavi, WHO, UNICEF, the World Bank, and the Pandemic Fund must now weigh that uncertainty against the cost of inaction — a calculation with no clean answer while the outbreak continues to grow.
The Bundibugyo strain of Ebola is spreading across the Democratic Republic of the Congo and Uganda with a speed that has alarmed global health authorities, and for the first time in this outbreak, there is no approved vaccine to deploy against it. The numbers are stark: 575 suspected cases, 51 confirmed infections, and 148 suspected deaths have been reported so far. The World Health Organization has declared it a Public Health Emergency of International Concern. The Africa Centres for Disease Control and Prevention has called it a Public Health Emergency of Continental Security. Yet the world's vaccine arsenal contains nothing specifically designed to stop this particular virus.
Into this gap steps an unlikely coalition. India's Serum Institute, the world's largest vaccine manufacturer, has joined forces with the University of Oxford and the Coalition for Epidemic Preparedness Innovations to accelerate development of an experimental vaccine based on the ChAdOx platform—the same technology that produced the Oxford-AstraZeneca vaccine during the COVID-19 pandemic, manufactured at scale by SII as Covishield. The partnership represents a calculated bet that speed and existing infrastructure can outpace the traditional timeline of vaccine development.
Two experimental candidates are under consideration, and they represent fundamentally different approaches to the same urgent problem. The first uses a recombinant vesicular stomatitis virus platform, the same technology behind Ervebo, the licensed vaccine for the Zaire strain of Ebola. But there are no doses available even for clinical testing, and manufacturing trial-ready supplies would take six to nine months. The second candidate, the one SII is backing, uses the ChAdOx vector. It has never been tested against Bundibugyo virus in animals or humans. But it has a decisive advantage: the manufacturing infrastructure already exists. SII's facilities are optimized for this platform. The company believes it can produce vaccine doses in twenty to thirty days.
A Serum Institute spokesperson framed the effort in terms of global responsibility rather than commercial opportunity. The company activated its emergency response framework the moment news of the outbreak arrived, the spokesperson said. Oxford's master viral seed would allow SII to rapidly inoculate its cell banks and begin production in what the company described as record time. This is the kind of agility that India's biopharmaceutical sector brought to the world during the COVID-19 pandemic, when SII became one of the largest producers of coronavirus vaccines globally.
The stakes of this decision are immense. Gavi, the Vaccine Alliance, has described the outbreak as deeply concerning because it is unfolding in conflict-affected and hard-to-reach regions where healthcare infrastructure is already fragile. More than 500 suspected cases and over 130 deaths have been reported in the DRC alone. The appearance of confirmed cases in Uganda underscores the risk of regional spread into densely populated urban areas. Gavi currently manages a global stockpile of about 500,000 doses of Ervebo, which has been deployed successfully during previous DRC outbreaks, including a vaccination campaign in September 2025 that immunized more than 47,000 people. But experts caution that this vaccine, designed for the Zaire strain, may offer little or no protection against Bundibugyo.
Dr. Vasee Moorthy, an adviser to the World Health Organization, recently warned that it could take up to nine months before a vaccine against this particular Ebola species is ready for deployment. That timeline assumes everything proceeds smoothly. The ChAdOx candidate could potentially compress that window, but only if early studies show promising immune responses. The rVSV candidate, while more closely related to the successful Ervebo model, faces severe manufacturing delays that could render it useless during the current outbreak.
This leaves regulators and global health agencies confronting a difficult calculation. Gavi, CEPI, WHO, the Africa CDC, UNICEF, the World Bank, and the Pandemic Fund are coordinating closely to evaluate whether any experimental candidates can be accelerated into emergency use. The ChAdOx platform may offer one important advantage in that race: speed. But that speed comes with a cost. The vaccine has not yet undergone animal testing or human trials for Bundibugyo virus disease. Regulators will need to balance urgency against safety and efficacy concerns—a calculation that has no easy answer when hundreds of people are already dying and the outbreak shows no signs of slowing.
Notable Quotes
Our manufacturing capabilities exist not just for commerce, but for global health security. We activated our emergency response framework the moment we received word of the outbreak.— Serum Institute of India spokesperson
It could take up to nine months before a vaccine against this particular Ebola species is ready for deployment.— Dr. Vasee Moorthy, WHO adviser
The Hearth Conversation Another angle on the story
Why does the fact that there's no approved vaccine for Bundibugyo change the calculus here? Isn't Ebola Ebola?
Because the strains are different enough that a vaccine designed for one may not protect against another. Ervebo works for Zaire. But Bundibugyo is a separate species. The immune system doesn't automatically transfer that protection across strains.
So SII is essentially saying they can manufacture something that hasn't been tested yet?
Not exactly. They're saying they can manufacture it quickly once the basic design is validated. But yes—there's no animal data, no human data. They're betting that the platform is well enough understood from COVID work that they can compress the usual timelines.
What's the actual risk here? What goes wrong if they move too fast?
You could deploy a vaccine that doesn't work, or worse, causes harm. You've wasted precious time and resources. You've also eroded trust in the vaccine itself if people get sick. But the flip side is that waiting nine months means hundreds more deaths from a preventable disease.
Is there any precedent for this kind of emergency acceleration?
COVID-19 showed it's possible. But that was with massive resources, multiple vaccine platforms being tested simultaneously, and a global population willing to accept risk. This is different—smaller outbreak, less infrastructure, less political will to take chances.
Why does SII's involvement matter specifically?
Manufacturing scale. They can actually produce millions of doses if the vaccine works. Oxford can design it. CEPI can fund it. But without SII's factories and expertise with this platform, you're stuck with theoretical solutions. India became the world's pharmacy during COVID because of this exact capability.
What happens if the ChAdOx candidate fails?
Then you're back to waiting for the rVSV platform, which takes six to nine months to manufacture. By then, the outbreak could have spread far beyond the DRC and Uganda. That's the real pressure driving this decision.